大理大学学报 ›› 2022, Vol. 7 ›› Issue (10): 28-31.

• 药学 • 上一篇    下一篇

某医院172例肺癌患者抗肿瘤药物使用情况分析

刘全义,和 菲,沈 磊*   

  1. 1.大理大学第一附属医院药剂科,云南大理 6710002.大理大学药学院,云南大理 671000

  • 收稿日期:2022-04-11 修回日期:2022-08-02 出版日期:2022-10-15 发布日期:2022-11-15
  • 通讯作者: 沈磊,副教授,博士,E-mail: shenlei@dali.edu.cn。
  • 作者简介:刘全义,主管药师,主要从事抗肿瘤药物治疗的临床药学研究。
  • 基金资助:

    大理市科技计划项目(2020KGB008);大理大学第一附属医院学科建设项目(DFYGG2022-29

Analysis of Utilization of Antitumor Drug in 172 Patients with Lung Cancer in a Hospital

Liu QuanyiHe FeiShen Lei*   

  1. 1. Department of PharmacyThe First Affiliated Hospital of Dali UniversityDaliYunnan 671000China2.College of PharmacyDali UniversityDaliYunnan 671000China

  • Received:2022-04-11 Revised:2022-08-02 Online:2022-10-15 Published:2022-11-15

摘要:

[摘要] 目的:分析大理大学第一附属医院肺癌患者抗肿瘤药物的使用情况并评价用药合理性。方法:选取该院2020年诊断为肺癌晚期的住院患者172例作为研究对象,回顾性分析肺癌患者治疗方案的合理性与用药安全性。结果:肺癌患者治疗方案选择合理,绝大部分为含铂双药方案;不合理用药集中在用药过程,主要为用法、用量不适宜,预处理不适宜及超说明书用药;用药后的不良反应主要为骨髓抑制。结论:肺癌患者的化疗过程仍存在不合理情况,医疗机构应重视抗肿瘤药物的合理性评价,进一步促进临床的规范、合理用药。

关键词: font-size:14px, ">肺癌, 抗肿瘤药物, 治疗方案, 不良反应

Abstract:

AbstractObjectiveTo analyze the utilization of antitumor drug in patients with lung cancer in the First Affiliated Hospital of Dali University and evaluate the rationality of drug use. MethodsA total of 172 inpatients diagnosed with advanced lung cancer in this hospital in 2020 were selected as the research objects to retrospectively analyze the rationality of the therapeutic regimen and medication safety for lung cancer patients. ResultsThe therapeutic regimens for patients with lung cancer were reasonableand most of them were platinum-containing dual-drug regimen. Irrational drug use mainly focused on the process of drug useincluding inappropriate usage and dosageinappropriate pretreatment and off-label drug use. The main adverse reaction after drug treatment was myelosuppression. ConclusionThere are still irrational situations in the chemotherapy process for the patients with lung cancer. Medical institutions should pay attention to the rationality evaluation of antitumor drugand further promote the standardized and rational use of drugs in clinical practice.

Key words:

"> font-size:10.5pt, ">lung cancer, antitumor drug, therapeutic regimen, adverse reaction

中图分类号: